Bristol-Myers Squibb (BMY) Earnings Date & Reports
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more
BMY is expected to report earnings to rise 1.90% to $1.61 per share on July 30
Bristol Myers Squibb (BMY) Q1 2026 Earnings Recap: Growth Portfolio Fuels Revenue Beat
Key Takeaways
- Bristol Myers Squibb reported Q1 2026 revenues of $11.5 billion, up 3% year-over-year (YoY), beating consensus estimates around $11.0 billion.
- Non-GAAP earnings per share (EPS) came in at $1.58, surpassing expectations of $1.44.
- Growth Portfolio revenues rose 12% to $6.2 billion, driven by strong sales of Eliquis, Opdivo, and newer launches like Camzyos and Breyanzi.
- Legacy Portfolio declined 6% to $5.3 billion amid generic pressures.
- Company reaffirmed full-year 2026 guidance, with revenues trending toward the upper end of $46.0–$47.5 billion and non-GAAP EPS of $6.05–$6.35.
- Shares surged over 5% in post-earnings trading, reflecting positive investor response.
Earnings Context and Why It Matters
Bristol Myers Squibb's Q1 2026 earnings provide critical insight into the company's transition from legacy blockbusters to a robust growth portfolio amid patent cliffs and generic competition. As a leading biopharmaceutical firm, BMY faces pressures from declining sales of older drugs like Revlimid, but strong demand for blood thinner Eliquis (apixaban) and oncology leader Opdivo (nivolumab) underscores resilience. Investors watch these results closely for signals on pipeline execution, margin trends, and ability to sustain revenue growth in a competitive biotech landscape. With reaffirmed guidance, the report reinforces BMY's strategic pivot toward high-growth therapies in immunology, cardiovascular, and hematology.
For the first quarter ended March 31, 2026, Bristol Myers Squibb delivered total revenues of $11.5 billion, a 3% increase YoY (1% excluding foreign exchange, or ex-FX) from $11.2 billion, topping analyst forecasts near $11.0 billion. The Growth Portfolio, comprising newer products, generated $6.2 billion, up 12% YoY (9% ex-FX), fueled by double-digit gains in Eliquis and contributions from launches like Camzyos (for hypertrophic cardiomyopathy) and Breyanzi (CAR-T therapy). In contrast, the Legacy Portfolio fell 6% to $5.3 billion due to generic erosion.
GAAP diluted EPS was $1.31, while non-GAAP EPS reached $1.58, exceeding consensus of $1.44—GAAP reflects standard accounting, while non-GAAP adjusts for one-time items like acquired in-process research and development (IPR&D) charges. U.S. revenues dipped 1% to $7.8 billion, offset by 11% international growth to $3.7 billion.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.
Market Reaction and Investor Sentiment
BMY shares jumped more than 5% immediately following the April 30 release, outperforming the broader healthcare sector, as the revenue beat and reaffirmed guidance alleviated concerns over legacy declines. Investor sentiment turned positive, with focus shifting to the Growth Portfolio's momentum and pipeline potential, though some noted EPS pressures from IPR&D costs.
Forward Outlook and Key Factors to Monitor
Bristol Myers Squibb reaffirmed its 2026 guidance, projecting total revenues of $46.0–$47.5 billion and non-GAAP EPS of $6.05–$6.35, now trending toward the upper ranges based on Q1 strength. This reflects expected 10%–15% worldwide growth for Eliquis versus 2025.
Investors should track quarterly Growth Portfolio execution, particularly uptake of recent launches like Camzyos and Reblozyl (for anemia), alongside Opdivo expansion in new indications. Patent expiry risks for legacy assets remain a headwind, balanced by pipeline milestones in oncology and immunology.
Broader factors include U.S. pricing dynamics, international reimbursement trends, and R&D productivity—watch for updates on Phase 3 readouts and potential business development deals. Cost management amid inflation will be key to margins.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor